F.D.A. Clears New Cancer-Fighting Drug From Roche


F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.

Latest News

Clean Energy Research to get Historic Investment during the United Nations
Investors Keenly Wait for OPEC Meeting; Oil Prices Move Up a Little
Amazon Testing Drones in Multiple International Locations
NextEra Agrees to Sell Two Texas Power Plants to Luminant
China’s Yuan Could be Named a Reserve Currency by the IMF
Rupert Murdoch Tweets Tribune Probably Selling Los Angeles Times
Black Friday Shopping “Uninspiring” in Brick and Mortar Stores; Shopping Trends
U.S. Crude Drops Further Due to Surplus Supply
CVC and CPPIB Outbid Others for a Possible Deal to Buy Petco for $4.7 Billion
US Government All Set to Introduce a New Law for Americans “Seriously Delinquent
Reportedly Pfizer Plans to Acquire Allergan in a Deal of $150 Billion or More
In October Most States Experienced a Drop in Unemployment Rate